Vaxart Inc. (VXRT) News
Filter VXRT News Items
VXRT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VXRT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VXRT News From Around the Web
Below are the latest news stories about VAXART INC that investors may wish to consider to help them evaluate VXRT as an investment opportunity.
Vaxart project agreement change ups funding for oral COVID vaccine candidateIn a regulatory filing, Vaxart (VXRT) stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. entered into an agreement with Advanced Technology International, the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Pursuant to the Project Agreement, the Company receives funding for a Phase 2b comparative study evaluating the Company’s oral pill XBB C |
Top Midday GainersVaxart (VXRT) said on Friday it secured a $4.6 million increase in funding under a project agreement |
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateSOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart’s COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator. “We are pleased to complete the enrollment of the sen |
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart. The awards consisted of stock options to purchase an aggregate of 61,000 shares of Vaxart’s common stock, whi |
Vaxart Third Quarter 2024 Earnings: Beats ExpectationsVaxart ( NASDAQ:VXRT ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.93m (up 135% from 3Q 2023). Net... |
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...Vaxart Inc (VXRT) reports significant progress in its COVID-19 and Norovirus programs, backed by strong governmental support and increased revenue. |
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue EstimatesVAXART (VXRT) delivered earnings and revenue surprises of 40% and 70.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsExpects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2024. “Our successful initiation of sentinel cohort dosing is a testament t |
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: C |
Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gainWhen you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far... |